Literature DB >> 33205544

Detection of circulating tumour cells enables early recurrence prediction in hepatocellular carcinoma patients undergoing liver transplantation.

Peng-Xiang Wang1, Yang Xu1, Yun-Fan Sun1, Jian-Wen Cheng1, Kai-Qian Zhou1, Sui-Yi Wu1, Bo Hu1, Ze-Fan Zhang1, Wei Guo2, Ya Cao3, Xiao-Wu Huang1, Jian Zhou1,4, Jia Fan1,4, Xin-Rong Yang1.   

Abstract

BACKGROUND & AIMS: Liver transplantation (LTx) is one of the most effective treatments for hepatocellular carcinoma (HCC); however, tumour recurrence after LTx often leads to poor outcomes. This study investigated the value of circulating tumour cells (CTCs) as a predictor of recurrence following LTx in patients with HCC.
METHODS: This analysis included 193 patients with HCC who underwent LTx at our institute and accepted pre- and post-operative CTC detection; 38 were selected for serial CTC monitoring. The predictive value of CTCs for tumour recurrence in patients with HCC following LTx was evaluated. Single-cell whole genome sequencing was used to characterize CTCs.
RESULTS: Overall, the CTC burden decreased after LTx (P < .05). Post-operative CTC count ≥ 1 per 5 mL peripheral blood was identified as a potential biomarker for predicting tumour recurrence after LTx, especially in patients with no detectable CTCs prior to LTx and negative tumour serological biomarkers. The predictive value of post-operative CTC count ≥ 1 per 5 mL blood was retained in patients who did not meet the Milan criteria, University of California San Francisco (UCSF) criteria, or Fudan criteria (all P < .05). Furthermore, post-operative serial CTC detection may be useful in post-surgical surveillance for HCC recurrence.
CONCLUSIONS: CTCs may be a useful biomarker to evaluate recurrence risk following LTx in patients with HCC. Evaluation based on CTC detection may enhance the post-transplant management of HCC, and improve the therapeutic efficacy of LTx.
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  circulating tumour cells; hepatocellular carcinoma; liver transplantation; prognosis; tumour recurrence

Year:  2020        PMID: 33205544     DOI: 10.1111/liv.14734

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  11 in total

1.  Epithelial-to-mesenchymal transition of circulating tumor cells and CD133 expression on predicting prognosis of thyroid cancer patients.

Authors:  Deyu Li; Na Li; Ying Ding
Journal:  Mol Clin Oncol       Date:  2022-08-01

2.  Guiding Value of Circulating Tumor Cells for Preoperative Transcatheter Arterial Embolization in Solitary Large Hepatocellular Carcinoma: A Single-Center Retrospective Clinical Study.

Authors:  Qiao Zhang; Feng Xia; Ali Mo; Weiming He; Jiazhen Chen; Weiqiao Zhang; Weiqiang Chen
Journal:  Front Oncol       Date:  2022-05-18       Impact factor: 5.738

Review 3.  The Role of Liquid Biopsy in Hepatocellular Carcinoma Prognostication.

Authors:  Ismail Labgaa; Augusto Villanueva; Olivier Dormond; Nicolas Demartines; Emmanuel Melloul
Journal:  Cancers (Basel)       Date:  2021-02-06       Impact factor: 6.639

Review 4.  Circulating Tumor Cells in Hepatocellular Carcinoma: A Comprehensive Review and Critical Appraisal.

Authors:  María Lola Espejo-Cruz; Sandra González-Rubio; Javier Zamora-Olaya; Víctor Amado-Torres; Rafael Alejandre; Marina Sánchez-Frías; Rubén Ciria; Manuel De la Mata; Manuel Rodríguez-Perálvarez; Gustavo Ferrín
Journal:  Int J Mol Sci       Date:  2021-12-03       Impact factor: 5.923

5.  Clinical Significance of Circulating Tumor Cells (CTCs) and Survivin on Predicting Prognosis in Thyroid Cancer Patients.

Authors:  Xun Weng; Yujiao Cai
Journal:  Dis Markers       Date:  2022-01-31       Impact factor: 3.434

6.  Combination of Preoperative Circulating Tumor Cell Count and Neutrophil-Lymphocyte Ratio for Prognostic Prediction in Hepatocellular Carcinoma Patients after Curative Hepatectomy.

Authors:  Hang-Hang Ni; Xi-Hua Yang; Cheng-Lei Yang; Qian Zhang; Jing-Xuan Xu; Lu-Nan Qi; Bang-De Xiang
Journal:  Biomed Res Int       Date:  2022-07-16       Impact factor: 3.246

Review 7.  Clinical applications of circulating tumor cells in hepatocellular carcinoma.

Authors:  Yinggang Hua; Jingqing Dong; Jinsong Hong; Bailin Wang; Yong Yan; Zhiming Li
Journal:  Front Oncol       Date:  2022-08-24       Impact factor: 5.738

Review 8.  Liquid Biopsy in Hepatocellular Carcinoma: Where Are We Now?

Authors:  Filippo Pelizzaro; Romilda Cardin; Barbara Penzo; Elisa Pinto; Alessandro Vitale; Umberto Cillo; Francesco Paolo Russo; Fabio Farinati
Journal:  Cancers (Basel)       Date:  2021-05-10       Impact factor: 6.639

Review 9.  Biomarkers for hepatocellular carcinoma based on body fluids and feces.

Authors:  Ming-Cheng Guan; Wei Ouyang; Ming-Da Wang; Lei Liang; Na Li; Ting-Ting Fu; Feng Shen; Wan-Yee Lau; Qiu-Ran Xu; Dong-Sheng Huang; Hong Zhu; Tian Yang
Journal:  World J Gastrointest Oncol       Date:  2021-05-15

Review 10.  Liver Transplantation for Hepatocellular Carcinoma: How Should We Improve the Thresholds?

Authors:  Tsuyoshi Shimamura; Ryoichi Goto; Masaaki Watanabe; Norio Kawamura; Yasutsugu Takada
Journal:  Cancers (Basel)       Date:  2022-01-14       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.